Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07293728 · ClinicalTrials.gov registry record · Phase 4
A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia
A Phase 4 study, sponsored by Oregon Health and Science University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT07293728 is a Phase 4 study that has not yet begun recruiting, run by Oregon Health and Science University. The registered enrollment target is 50 participants.
The verdict
NCT07293728, a Phase 4 study, has not yet begun recruiting, sponsored by Oregon Health and Science University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is an open-label, randomized feasibility trial in which patients admitted to Oregon Health \& Science University (OHSU) after a pregnancy complicated by preeclampsia who are considering a progestin-only pill contraception postpartum will be randomized to norethindrone or drospirenone for 6 weeks following hospital discharge.
Interventions
- DRUG Drospirenone
- DRUG Norethindrone 0.35 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07293728
The ClinicalTrials.gov registry entry for NCT07293728 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Drospirenone is the first listed.
NCT07293728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07293728 about?
NCT07293728 is a clinical study titled "A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia". This is an open-label, randomized feasibility trial in which patients admitted to Oregon Health \& Science University (OHSU) after a pregnancy complicated by preeclampsia who are considering a progestin-only pill contraception postpartum will be randomized to norethindrone or drospirenone for 6 week...
What is the current status of trial NCT07293728?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2026-07. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07293728?
The interventions under investigation include: Drospirenone (DRUG), Norethindrone 0.35 MG (DRUG).
Who is sponsoring clinical trial NCT07293728?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.